» Articles » PMID: 37535903

Construction of Ferrocene-Containing Membrane-Bound Nanofibers for the Redox Control of Cancer Cell Death and Cancer Therapy

Overview
Journal Nano Lett
Specialty Biotechnology
Date 2023 Aug 3
PMID 37535903
Authors
Affiliations
Soon will be listed here.
Abstract

Precise manipulation of cancer cell death by harnessing reactive oxygen species (ROS) is a promising strategy to defeat malignant tumors. However, it is quite difficult to produce active ROS with spatial precision and regulate their biological outcomes. We succeed here in selectively generating short-lived and lipid-reactive hydroxyl radicals (OH) adjacent to cancer cell membranes, successively eliciting lipid peroxidation and ferroptosis. DiFc-K-pY, a phosphorylated self-assembling precursor that consists of two branched Fc moieties and interacts specifically with epidermal growth factor receptor, can produce membrane-bound nanofibers and enrich ferrocene moieties on cancer cell membranes in response to alkaline phosphatase. Within the acidic tumor microenvironment, DiFc-K-pY nanofibers efficiently convert tumoral HO to active OH around the target cell membranes via Fenton-like reactions, leading to lipid peroxidation and ferroptosis with good cellular selectivity. Our strategy successfully prevents tumor progression with acceptable biocompatibility through intratumoral administration.

Citing Articles

How does ferrocene correlate with ferroptosis? Multiple approaches to explore ferrocene-appended GPX4 inhibitors as anticancer agents.

Li W, Yu J, Wang J, Fan X, Xu X, Wang H Chem Sci. 2024; 15(27):10477-10490.

PMID: 38994406 PMC: 11234876. DOI: 10.1039/d4sc02002b.


Ferroptosis: emerging roles in lung cancer and potential implications in biological compounds.

Liang Q, Wang Y, Li Y, Wang J, Liu C, Li Y Front Pharmacol. 2024; 15:1374182.

PMID: 38783959 PMC: 11111967. DOI: 10.3389/fphar.2024.1374182.


Alleviating Recombinant Tissue Plasminogen Activator-induced Hemorrhagic Transformation in Ischemic Stroke via Targeted Delivery of a Ferroptosis Inhibitor.

Geng Y, Qiu L, Cheng Y, Li J, Ma Y, Zhao C Adv Sci (Weinh). 2024; 11(24):e2309517.

PMID: 38647405 PMC: 11199968. DOI: 10.1002/advs.202309517.


The ferroptosis landscape in acute myeloid leukemia.

Ma Z, Ye W, Huang X, Li X, Li F, Lin X Aging (Albany NY). 2023; 15(22):13486-13503.

PMID: 38032290 PMC: 10713399. DOI: 10.18632/aging.205257.